DK1084146T3 - Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf - Google Patents

Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf

Info

Publication number
DK1084146T3
DK1084146T3 DK99950347T DK99950347T DK1084146T3 DK 1084146 T3 DK1084146 T3 DK 1084146T3 DK 99950347 T DK99950347 T DK 99950347T DK 99950347 T DK99950347 T DK 99950347T DK 1084146 T3 DK1084146 T3 DK 1084146T3
Authority
DK
Denmark
Prior art keywords
mastocytes
degranulation
inhibiting
hybrid protein
basophils
Prior art date
Application number
DK99950347T
Other languages
Danish (da)
English (en)
Inventor
Hans Bigalke
Juergen Frevert
Original Assignee
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh filed Critical Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Application granted granted Critical
Publication of DK1084146T3 publication Critical patent/DK1084146T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
DK99950347T 1998-05-13 1999-05-12 Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf DK1084146T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13
PCT/EP1999/003272 WO1999058571A2 (fr) 1998-05-13 1999-05-12 Proteine hybride pour l'inhibition de la degranulation des mastocytes et son utilisation

Publications (1)

Publication Number Publication Date
DK1084146T3 true DK1084146T3 (da) 2003-02-03

Family

ID=7867540

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99950347T DK1084146T3 (da) 1998-05-13 1999-05-12 Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf

Country Status (21)

Country Link
EP (1) EP1084146B1 (fr)
JP (1) JP4549533B2 (fr)
KR (1) KR100580541B1 (fr)
CN (1) CN1241945C (fr)
AT (1) ATE227739T1 (fr)
AU (1) AU755513B2 (fr)
BR (1) BR9910359A (fr)
CA (1) CA2331274C (fr)
CU (1) CU22997A3 (fr)
CZ (1) CZ294376B6 (fr)
DE (1) DE59903410D1 (fr)
DK (1) DK1084146T3 (fr)
ES (1) ES2187200T3 (fr)
HU (1) HUP0103601A3 (fr)
IL (2) IL139478A0 (fr)
MX (1) MXPA00011148A (fr)
NO (1) NO328361B1 (fr)
PL (1) PL201879B1 (fr)
PT (1) PT1084146E (fr)
RU (1) RU2214420C2 (fr)
WO (1) WO1999058571A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
JP2004521067A (ja) * 2000-06-28 2004-07-15 サンダース,イラ 動物(哺乳動物)における有用な用途を目的とする破傷風毒素の使用方法
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
RU2255761C1 (ru) * 2004-07-01 2005-07-10 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Препарат для лечения мышечных дистоний из токсина культуры clostridium botulinum и способ его получения
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (ko) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는면역조절제
EP2310028B1 (fr) 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Protéines de fusion pour leur utilisation dans le traitement de l'acromégalie
WO2009150470A2 (fr) 2008-06-12 2009-12-17 Syntaxin Limited Suppression de cancers
AU2009275846B2 (en) * 2008-07-31 2014-09-25 L'institut National Des Sciences Appliquees (Insa) Constructs and methods for the production and secretion of polypeptides
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (zh) * 2010-05-27 2014-05-14 四川大学 重组IgE-Fc-抗EGFR单链抗体融合蛋白及其制备方法和用途
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
WO2016110662A1 (fr) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Neurotoxines cationiques
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (fr) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production de neurotoxines clostridiales activées
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
BR112023020057A2 (pt) 2021-03-30 2024-03-12 Ipsen Biopharm Ltd Tratamento de dor e distúrbios inflamatórios
BR112023018473A2 (pt) 2021-03-30 2023-11-14 Ipsen Biopharm Ltd Neurotoxinas clostridiais cataliticamente inativas para o tratamento de dor e distúrbios inflamatórios
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (pl) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1237972A1 (ru) * 1983-01-07 1986-06-15 Киевский научно-исследовательский институт отоларингологии им.проф.А.И.Коломийченко Способ определени активности ингибитора дегранул ции мастоцитов
US4902495A (en) * 1986-07-22 1990-02-20 The United States Of America As Represented By The Department Of Health And Human Services IgE Fc directed delivery system
RU2030914C1 (ru) * 1992-09-15 1995-03-20 Людмила Михайловна Огородова Средство, предупреждающее дегрануляцию тучных клеток
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
CA2331274C (fr) 2010-04-06
CA2331274A1 (fr) 1999-11-18
JP4549533B2 (ja) 2010-09-22
NO328361B1 (no) 2010-02-01
EP1084146A2 (fr) 2001-03-21
CN1300295A (zh) 2001-06-20
KR100580541B1 (ko) 2006-05-16
MXPA00011148A (es) 2003-04-22
ATE227739T1 (de) 2002-11-15
IL139478A (en) 2008-06-05
NO20005637L (no) 2000-11-08
DE59903410D1 (de) 2002-12-19
WO1999058571A3 (fr) 2000-02-03
ES2187200T3 (es) 2003-05-16
IL139478A0 (en) 2001-11-25
CN1241945C (zh) 2006-02-15
RU2214420C2 (ru) 2003-10-20
AU4260599A (en) 1999-11-29
NO20005637D0 (no) 2000-11-08
CU22997A3 (es) 2004-10-12
KR20010042825A (ko) 2001-05-25
JP2002514659A (ja) 2002-05-21
PL344752A1 (en) 2001-11-19
CZ294376B6 (cs) 2004-12-15
PT1084146E (pt) 2003-02-28
HK1036994A1 (en) 2002-01-25
PL201879B1 (pl) 2009-05-29
HUP0103601A2 (hu) 2002-01-28
BR9910359A (pt) 2001-01-09
WO1999058571A2 (fr) 1999-11-18
CZ20004161A3 (cs) 2001-04-11
AU755513B2 (en) 2002-12-12
HUP0103601A3 (en) 2004-06-28
EP1084146B1 (fr) 2002-11-13

Similar Documents

Publication Publication Date Title
PL344752A1 (en) Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
DK1255826T3 (da) Automatisering af proteindesign for proteinbiblioteker
CY1119024T1 (el) Καθαρισμος πρωτεϊνης
ATE431834T1 (de) Prozess zur trennung von proteinen
ATE309201T1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
ATE465748T1 (de) Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung
ATE317441T1 (de) Cathepsin-02-protease
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE50307984D1 (de) Streptavidin-Bindungspeptid
DE60135412D1 (de) Schaltung zur zeitlichen Detektion von empfangenen Pfaden in Direktsequenz-CDMA-System
FI961044A7 (fi) Kininogeeni-inhibiittorit
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
IL145689A0 (en) Methods
IL176479A0 (en) Methods and compositions for identifying rna-binding proteins
ATE323763T1 (de) Dna & protein bindende miniatur proteine
DK1268514T3 (da) Fremgangsmåde til oprensning af særdeles anioniske proteiner
DK1117682T3 (da) Chi-conotoksin-peptider som inhibitorer af neuronale amintransportere
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
BRPI0416201A (pt) métodos para purificação de toxina coqueluche e peptìdios neles utilizáveis
DK1078072T3 (da) Nye peptidfragmenter til oprensning af proteiner
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
NO20044186L (no) Peptid-deformylaseinhibitorer